P2RY2 and glaucoma: Furthermore, our bioinformatic analysis was able to identify several druggable targets for glaucoma treatment, e.g., the A1 and A2A adenosine receptors, along with the 5-hydroxytryptamine 2A and purinergic P2Y2 receptors, which have already been investigated in other studies.